# Rocgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rocgene

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.rocgene.com
- Latest round: Series B (Jan 17, 2025)
- Investors on record: 2

## About

Founded in 2016 and based in Beijing, China, RocGene (Beijing) Technology Co., Ltd., dba Rocgene, operates as a biotechnology company that focuses on the development and production of molecular diagnostic products. It was recognized as the National High-tech Enterprise. Qiuzhen Guo, the company's founder and CEO, was previously general manager of PerkinElmer's life science business in Greater China. In February 2026, Rocgene raised Series B+ funding.
Rocgene specializes in the design and manufacturing of molecular diagnostic instruments and reagents. Products include medical fluorescence quantitative PCR instruments, molecular detection cartridges, DNA detection kits, etc. Products can be used in vitro diagnostics, disease prevention, life sciences, and veterinary medicine.
The company generates revenue by selling molecular diagnostic products.

## Funding rounds

- Series B, Jan 17, 2025 — Hantang Fund Management, Taiping Innovation Investment Management

## Investors

- Hantang Fund Management (https://capitalatlas.ai/funds/hantang-fund-management) — Series B
- Taiping Innovation Investment Management — Series B